178 related articles for article (PubMed ID: 31025302)
1. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.
Telford C; Bertranou E; Large S; Phelps H; Ekman M; Livings C
Pharmacoecon Open; 2019 Dec; 3(4):559-570. PubMed ID: 31025302
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant for hormone-sensitive metastatic breast cancer.
Lee CI; Goodwin A; Wilcken N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011093. PubMed ID: 28043088
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Zhang J; Huang Y; Wang C; He Y; Zheng S; Wu K
Medicine (Baltimore); 2017 Aug; 96(33):e7846. PubMed ID: 28816986
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patients with advanced breast cancer in the United Kingdom.
Das R; Cope S; Ouwens M; Turner P; Howlett M
Clin Ther; 2013 Mar; 35(3):246-260.e5. PubMed ID: 23453402
[TBL] [Abstract][Full Text] [Related]
6. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.
Reinert T; Barrios CH
Ther Adv Med Oncol; 2017 Nov; 9(11):693-709. PubMed ID: 29344106
[TBL] [Abstract][Full Text] [Related]
7. First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis.
Liao W; Huang J; Wu Q; Wen F; Zhang N; Zhou K; Bai L; Li Q
Breast Cancer; 2020 May; 27(3):399-404. PubMed ID: 31853795
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
10. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
12. Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.
Sabale U; Ekman M; Thunström D; Telford C; Livings C
Pharmacoecon Open; 2017 Dec; 1(4):279-290. PubMed ID: 29441507
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
14. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
[TBL] [Abstract][Full Text] [Related]
15. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
16. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Robertson JF; Lindemann JP; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Emerson L; Dean A; Ellis MJ
Breast Cancer Res Treat; 2012 Nov; 136(2):503-11. PubMed ID: 23065000
[TBL] [Abstract][Full Text] [Related]
19. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C; Keam SJ
Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Picot J; Kalita N; Gaisford W; Harris P; Onyimadu O; Cooper K
Pharmacoeconomics; 2019 Jun; 37(6):753-762. PubMed ID: 30328052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
